Dosage Forms

Articles

A comprehensive understanding of what makes mRNA vaccines tick is crucial in charting the future of the market.

Charting the Future of Vaccines

Podcasts

Jeff Fischer, co-founder and president of Longhorn Vaccines and Diagnostics, discusses the history and ongoing development of both protein- and mRNA-based vaccines.

Drug Solutions Podcast: Evaluating the Vaccine Marketplace

EMA looks to focus on mRNA vaccines because their classification depends on the target and/or whether they are obtained chemically or biologically. 

EMA Aims to Develop Guideline for mRNA Vaccines

The acquisition will continue to strengthen the area of conjugate vaccines and bioconjugate drugs and will expand Biosynth’s capabilities from good manufacturing practice facilities located in Berlin, Germany.

Biosynth Acquires Celares for Growing Conjugate Vaccine Market

Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy. 

Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured.

Transduction for AAV with Sean Hart

World leaders have set ambitious goals to respond more swiftly to the next pandemic, including the US goal to design, test, and review a new vaccine just 100 days after a pandemic declaration. 

mRNA Global Alliance Tests the Waters at BIO

Feliza Mirasol is the science editor for 

invoX Pharma has made a second tranche of investment in pHion Therapeutics to support further development of next-generation mRNA vaccines.

invoX Pharma Invests in pHion Therapeutics to Develop Next-Generation mRNA Vaccines

The data, published in the scientific journal Nature, demonstrated that half of patients developed T cells that could potentially fight pancreatic ductal adenocarcinoma.

BioNTech and Roche Publish Personalized Vaccine Data

Vibha Jawa, executive director at Bristol Myers Squibb, discusses foreign epitopes recognition from what should be fully human antibody therapies.